Core Viewpoint - Bausch + Lomb Corporation will release its first-quarter financial results for 2026 on April 29, 2026, and will host a conference call to discuss these results and provide a business update [1]. Group 1: Financial Results Announcement - The financial results for the first quarter of 2026 will be released on April 29, 2026 [1]. - A conference call and live webcast will take place at 8 a.m. ET on the same day to discuss the results [1]. - All relevant materials will be available on the Investor Relations section of the Bausch + Lomb website prior to the call [1]. Group 2: Company Overview - Bausch + Lomb is a leading global eye health company focused on helping people see better to live better [2]. - The company has a long history of evolving with the changing needs of patients and customers, emphasizing innovation and improving eye health care standards [2]. - Bausch + Lomb offers a wide range of products, including contact lenses, prescription products, over-the-counter options, and surgical devices [2].

Core Insights - Bausch + Lomb reported a record fourth quarter and full-year performance for 2025, driven by broad-based revenue growth and accelerating profitability [4][6] - The company achieved an adjusted EBITDA of $330 million in Q4, up 27%, with a margin of 23.5%, marking the highest level since its IPO [1][6] - Total revenue for Q4 was $1.405 billion, reflecting a 7% increase on a constant-currency basis, while full-year revenue reached $5.101 billion, up 5% [2][6] Financial Performance - Full-year adjusted EBITDA was $891 million, with an adjusted EBITDA margin of 17.5% [1] - The company expects 2026 revenue guidance of $5.375 to $5.475 billion, representing 5% to 7% constant-currency growth [5][15] - Adjusted EBITDA for 2026 is projected to be between $1.0 billion and $1.05 billion, implying an EBITDA margin of approximately 19% [5][16] Segment Performance - Vision Care segment revenue in Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [7] - The surgical segment reported Q4 revenue of $249 million, up 3%, and full-year revenue of $894 million, up 4% [8] - In pharmaceuticals, Q4 revenue was $378 million, up 14%, with full-year revenue of $1.284 billion, up 6% [9] Product Highlights - The dry-eye franchise saw significant growth, with MIEBO prescriptions increasing by 113% year-over-year, and peak sales potential raised from approximately $500 million to over $600 million [6][12] - XIIDRA also showed record quarterly prescriptions, with expected improved net pricing to drive revenue growth [13] - The consumer dry eye portfolio generated $116 million in Q4 revenue, up 6%, led by Blink growth of 33% [11] Market Dynamics - The overall dry eye market is expanding due to factors such as aging, environmental conditions, and increased screen time, with only about one in ten patients currently treated with prescription therapy [14] - Management noted that Q1 is typically the lowest quarter and Q4 the highest, with this seasonality expected to become more pronounced as the dry eye franchise grows [18] Future Outlook - The company plans to launch new consumer products, including PreserVision AREDS 3 and Blink Triple Care, in early 2026 [19] - A CE Mark submission for a next-generation femtosecond laser, Silera, is anticipated soon, with expected approval in the second half of the year [19] - Management is optimistic about returning to pre-recall levels in the surgical segment and expects to stop referencing the enVista recall in future earnings calls [21]

Core Viewpoint - Bausch + Lomb Corporation has successfully closed a credit agreement refinancing, entering into a fourth amendment to its existing credit agreement, which includes a new tranche of term B loans totaling $2,802,125,000 to refinance existing loans due in 2028 and 2031 [1] Group 1: Credit Agreement Details - The new Replacement Term Loans have an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026 [2] - The applicable margin for the Replacement Term Loans is set at 3.75% per annum for loans tied to term SOFR and 2.75% per annum for those tied to the alternate base rate, reflecting a reduction of 0.50% and 0.25% respectively from previous loans [2] - The maturity date for the Replacement Term Loans is January 15, 2031, which aligns with the maturity date of the previously existing loans, effectively extending the maturity of the First Incremental Term Loans from September 29, 2028 [2] Group 2: Company Overview - Bausch + Lomb is a leading global eye health company focused on improving vision and quality of life for individuals worldwide, with a commitment to innovation in eye care [3] - The company has a diverse product portfolio that includes contact lenses, prescription products, over-the-counter options, and surgical devices, aimed at enhancing patient outcomes [3]

Core Viewpoint - Bausch + Lomb Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to eye health and innovation [1]. Group 1: Company Presentation - The presentation will feature Chairman and CEO Brent Saunders, Executive Vice President and CFO Sam Eldessouky, and Chief Medical Officer Yehia Hashad, MD [1]. - The event is scheduled for January 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) [1]. Group 2: Investor Relations - A live webcast and audio archive of the event will be accessible on the Investor Relations page of the Bausch + Lomb website [2]. Group 3: Company Overview - Bausch + Lomb has a mission to help people see better to live better, with a history of nearly two centuries in evolving to meet patient and customer needs [3]. - The company focuses on innovation and improving standards of care in eye health, offering a range of products from contact lenses to surgical devices [3].

Core Viewpoint - Bausch + Lomb Corporation is refinancing its outstanding term B loans with a new tranche of Replacement Term Loans amounting to $2,802,125,000, aimed at extending maturity and reducing interest rates on existing loans [1]. Financial Summary - The Replacement Term Loans will refinance all outstanding term B loans due in 2031 and 2028, with a maturity date of January 15, 2031, which extends the maturity of the First Incremental Term Loans from September 29, 2028 [1]. - The applicable margin for the Replacement Term Loans is set at 3.75% per annum for loans referenced to term SOFR and 2.75% per annum for loans referenced to the alternate base rate, representing a reduction of 0.50% and 0.25% per annum for the respective loans [1]. Transaction Timeline - The transactions related to the Replacement Term Loans are expected to close in the first quarter of 2026, although there are no guarantees that they will be completed as planned [2]. Company Overview - Bausch + Lomb has a long-standing mission to enhance eye health and improve the quality of life for individuals globally, with a diverse product range including contact lenses, prescription products, and surgical devices [3].

Group 1 - Bausch + Lomb Corporation (NYSE:BLCO) has seen an 8.59% increase in share price recently, but Wall Street maintains a cautious outlook on the stock [1] - The company presented its growth strategy on November 13, targeting a compound annual growth rate (CAGR) of 5% to 7% through 2028, driven by product launches and overall growth [2] - Bausch + Lomb aims for an adjusted EBITDA of around 23% by 2028 while reaffirming its guidance for 2025 [2] Group 2 - Analysts have mixed ratings on Bausch + Lomb, with Barclays reiterating a Hold rating and a price target of $17, while Bank of America Securities maintains a Sell rating with a price target of $13 [3] - Concerns have been raised regarding the company's optimistic growth projections, which some analysts believe reflect only a best-case scenario and may be overestimated [4] - The growth targets are heavily reliant on execution rather than innovation, increasing the associated risk [4] Group 3 - Bausch + Lomb is recognized as a leading company in eye health, focusing on products such as contact lenses, pharmaceuticals, and surgical equipment [5]

Core Message - The company is outlining a three-year plan aimed at achieving profitable growth and improving financial margins by approximately 600 basis points over the next three years [2][4]. Financial Strategy - The plan includes a focus on financial excellence, with a commitment to grow above market rates and enhance margins through various initiatives [2]. - The company aims to modernize its manufacturing footprint, which has been described as somewhat outdated, to create efficiencies in manufacturing and supply chain [5]. Business Segments - The surgical segment is expected to be the largest contributor to margin expansion, particularly through the introduction of higher premium intraocular lenses and implants [4]. - The company is also focusing on a diverse product mix across its consumer, pharmaceuticals, and surgical businesses to drive higher-margin products through its pipeline and R&D efforts [3]. Capital Allocation and M&A - The company is adopting a disciplined capital allocation approach, with a focus on small M&A and licensing, primarily for intellectual property to develop new medicines or products [6]. - There is a commitment to achieve a leverage ratio of three to three and a half times by 2028, aiming for an investment-grade credit rating [6]. Impact of Tariffs - Tariffs are impacting the company by approximately 40 basis points of margin this year, equating to about $20 million, primarily due to reciprocal tariffs affecting exports to China and Europe [7][8]. - The company is planning to shift some production from the U.S. to Europe and Asia in response to these tariffs [9][10]. Future Outlook - The company is preparing for a long-term environment of tariffs, indicating that it is planning around a new baseline for revenue impacted by tariffs [12]. - There are ongoing concerns about myopia in children due to screen time, and the company is developing a contact lens specifically designed for kids that incorporates therapeutic correction [20].

Core Insights - Bausch + Lomb Corporation will hold an investor day on November 13, 2025, at the New York Stock Exchange [1] - Chairman and CEO Brent Saunders will provide an update on the company's transformation and strategic outlook [1] - Executive Vice President and Chief Financial Officer Sam Eldessouky will share details on a three-year plan to drive sustainable growth [1]

Core Viewpoint - Bausch + Lomb Corporation is set to release its third-quarter financial results on October 29, 2025, and will provide a business update during a conference call and live webcast [1] Financial Results - The third-quarter financial results will be discussed in detail during the conference call scheduled for 8 a.m. ET on the release date [1] Investor Relations - All relevant materials regarding the financial results and business update will be available on the Investor Relations section of the Bausch + Lomb website prior to the conference call [1]

Group 1 - Acadia Healthcare Company, Inc. (ACHC) has been added to the Zacks Rank 5 (Strong Sell) List due to a 1.5% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Bausch + Lomb Corporation (BLCO) is also on the Zacks Rank 5 (Strong Sell) List, with a 6% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Concrete Pumping Holdings, Inc. (BBCP) has seen a significant 70.8% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days, leading to its inclusion in the Zacks Rank 5 (Strong Sell) List [2]